Related Experiment Video
Updated: Jun 16, 2026

Whole Genome Sequencing of Candida glabrata for Detection of Markers of Antifungal Drug Resistance
Published on: December 28, 2017
Antifungal drug resistance of oral fungi
Masakazu Niimi1, Norman A Firth, Richard D Cannon
1Department of Oral Sciences, School of Dentistry, University of Otago, 310 Great King Street, Dunedin, 9016, New Zealand.
Abstract:
Fungi comprise a minor component of the oral microbiota but give rise to oral disease in a significant proportion of the population. The most common form of oral fungal disease is oral candidiasis, which has a number of presentations. The mainstay for the treatment of oral candidiasis is the use of polyenes, such as nystatin and amphotericin B, and azoles including miconazole, fluconazole, and itraconazole. Resistance of fungi to polyenes is rare, but some Candida species, such as Candida glabrata and C. krusei, are innately less susceptible to azoles, and C. albicans can acquire azole resistance. The main mechanism of high-level fungal azole resistance, measured in vitro, is energy-dependent drug efflux. Most fungi in the oral cavity, however, are present in multispecies biofilms that typically demonstrate an antifungal resistance phenotype. This resistance is the result of multiple factors including the expression of efflux pumps in the fungal cell membrane, biofilm matrix permeability, and a stress response in the fungal cell. Removal of dental biofilms, or treatments to prevent biofilm development in combination with antifungal drugs, may enable better treatment and prevention of oral fungal disease.
Insights
Oral fungi cause disease, with candidiasis being common. Antifungal resistance in biofilms, often due to efflux pumps, complicates treatment, suggesting combined therapies are needed.
Area of Science:
- Microbiology
- Oral Health
- Mycology
Background:
- Fungi are a minor part of the oral microbiota but can cause significant oral disease.
- Oral candidiasis is the most common oral fungal infection, presenting in various forms.
- Current treatments for oral candidiasis include polyenes (e.g., nystatin) and azoles (e.g., fluconazole).
Purpose of the Study:
- To review the mechanisms of antifungal resistance in oral fungi.
- To explore the role of biofilms in antifungal resistance.
- To discuss strategies for improving the treatment and prevention of oral fungal diseases.
Main Methods:
- Review of existing literature on oral fungal microbiota, oral candidiasis, antifungal agents, and resistance mechanisms.
- Analysis of factors contributing to antifungal resistance in fungal biofilms.
- Discussion of therapeutic approaches combining antifungal drugs with biofilm disruption.
Main Results:
- Resistance to polyenes is rare, but some Candida species exhibit innate azole resistance, and Candida albicans can acquire it.
- Energy-dependent drug efflux is a primary mechanism for high-level azole resistance in fungi.
- Oral fungal biofilms exhibit increased antifungal resistance due to efflux pumps, matrix permeability, and cellular stress responses.
Conclusions:
- Multispecies oral biofilms significantly contribute to antifungal resistance.
- Combined therapies targeting both fungal cells and biofilm structures are crucial for effective treatment and prevention of oral fungal diseases.
- Further research into biofilm-disrupting agents and combination therapies is warranted.
Related Concept Videos
Antifungal Agents
Candidiasis
Fungal Group Zygomycota
Antimicrobial Effectiveness
Development of Antibiotic Resistance
Clinical Significance of Antibiotic Resistance

